Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual General Meeting of Shareholders held by ProKidney Corp. on June 29, 2023. The company is incorporated in the Cayman Islands and its Class A ordinary shares trade on The Nasdaq Stock Market under the symbol PROK.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and shareholder voting results.
Material Changes and Voting Results
Shareholders voted on two primary matters at the Annual General Meeting:
- Election of Directors: Shareholders elected three nominees to the Board of Directors for three-year terms expiring in 2026. All nominees received overwhelming support:
- William F. Doyle: 204,688,357 votes For; 86,755 Against; 59,329 Abstain.
- Alan M. Lotvin, M.D.: 204,717,013 votes For; 86,192 Against; 31,236 Abstain.
- Brian J. G. Pereira, M.D.: 204,658,435 votes For; 84,994 Against; 91,012 Abstain.
- Ratification of Auditors: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes: 211,255,952 For; 15,231 Against; 234 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the election of the three new members.
- Confirm the engagement of Ernst & Young LLP for the 2023 fiscal year audit.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.